Introduction
============

Ovarian cancer is the eighth most common cancer and the seventh leading cause of cancer-associated mortality in women worldwide. It is the second highest cause of mortality among female reproductive malignancies and accounts for 140,200 mortalities each year. The estimated incidence and number of mortalities in the USA from ovarian cancer is 21,980 cases and 14,270 mortalities, respectively, for 2014 ([@b1-ol-0-0-6590],[@b2-ol-0-0-6590]). Ovarian cancer is the fourth most common malignancy in women and is the leading cause of gynecological cancer-associated mortality. Poland is one of the countries with high morbidity rates for ovarian carcinoma. Epidemiological data show steady rise of ovarian cancer incidence. Due to late-onset symptoms, ovarian cancer is mainly diagnosed in an advanced stage. In total, 60--70% of patients present with stage III or IV disease and are therefore associated with poor survival. The International Federation of Gynecology and Obstetrics (FIGO) staging classification in ovarian cancer has an independent prognostic role. The major role of the staging system is not only to provide universal terminology that may be used in different oncological hospitals worldwide, but it also informs us about the prognosis and outcome prediction subsequent to specific treatment. The majority of ovarian cancer patients are diagnosed with late-stage disease as the asymptomatic progression is poorly understood, and an efficient screening strategy is not presently available ([@b3-ol-0-0-6590]--[@b5-ol-0-0-6590]). The current standard first-line treatment for advanced ovarian cancer includes a combination of surgical debunking and standard systemic platinum-based chemotherapy with carboplatin and paclitaxel ([@b6-ol-0-0-6590],[@b7-ol-0-0-6590]). This standard treatment results in \>80% response rates and 40--60% complete responses; however, the majority of patients with advanced disease (stages III--IV) will eventually relapse, even with initial disease response. Improvement in survival has also been poor in ovarian cancer. Gene expression-based tools for the prediction of patient prognosis subsequent to surgery or chemotherapy are currently available for certain cancers. The prediction of cancer prognosis using molecular signatures is a popular research field, within which a wide variety of approaches have been considered ([@b7-ol-0-0-6590]). Popular RNA or protein expression measurement techniques include cDNA hybridization microarrays, end-point and quantitative reverse transcription polymerase chain reaction (PCR), and immunohistochemistry approaches ([@b8-ol-0-0-6590]). Although a deeper understanding of this disease has been attained, relapse continues to occur in 70% of patients 18 months following the first-line treatment. Therefore, it is crucial to develop a novel drug that effectively impacts on ovarian cancer, particularly one that is resistant to current chemotherapy. The 5-year survival rate of ovarian cancer patients with stage I is 92%. However, patients diagnosed in the late stage have poor prognosis, with a 5-year survival rate of only 19% for stage IV patients. The median progression-free survival time ranges between 16 and 21 months, and the median overall survival time ranges between 24 and 60 months ([@b9-ol-0-0-6590],[@b10-ol-0-0-6590]). Subsequent to repeated cycles of chemotherapy, recurrent ovarian cancer eventually develops resistance to numerous available cytotoxic agents. As a result, studies into the mechanisms of drug-resistance, biomarkers for drug resistance, and the development of new-targeted therapies have been the subject of numerous ovarian cancer studies ([@b11-ol-0-0-6590]). Although patients receiving standard therapy, including surgical cytoreduction and platinum-based combination chemotherapies, may have an initial favorable response, the majority of patients experience relapse within 5 years ([@b12-ol-0-0-6590]). Consequently, there is an urgent requirement for novel treatments for this deadly disease.

The aim of the present study was to identify genes of which the expression may be used to predict survival time or prognosis in ovarian cancer patients treated witch chemotherapy. As aforementioned, the presence of resistance to the chemotherapy agent administered dramatically affects the survival of a patient. It is therefore reasonable to expect the gene signatures identified to include genes responsible for chemoresistance, which will affect the mechanism of action of the drug. Gene or protein expression is an important issue of chemoresistance and survival prediction in ovarian cancer. The concept of identifying gene signatures is popular, but requires careful handling to extract the information required for this to be successful. There are certain previous studies that investigated the differing response of different types of ovarian cancer to chemotherapy ([@b13-ol-0-0-6590]). Identification of biomarkers that can reliably predict drug sensitivity and resistance is extremely important.

Materials and methods
=====================

In the present study, the research group consisted of patients treated at the Surgical Clinic of the Gynecology and Obstetrics Gynecological Clinical Hospital, Poznan University of Medical Sciences (Poznan, Poland) between May 2006 and November 2014. Of the 2,000 patients, four who suffered from ovarian serum carcinoma were chosen. Additional eligibility criteria were a similar severity (FIGO stage IIIC) at the time of diagnosis, treatment undertaken in accordance with the same schedule, and an extremely good response to treatment or a lack of response to treatment. Finally, two patients who had an exceptionally good response to treatment and two patients who did not respond to treatment were selected. A detailed description of the therapeutic effects of the patients enrolled in the present study is subsequently reported. Informed consent was obtained from all patients, and ethical approval was provided by the Bioethics Committee of Poznan University of Medical Sciences.

The tissue samples were collected from neoplastic lesions removed during surgery prior to starting drug therapy. The tissues were stored in paraffin blocks.

### Case reports

#### Case 1

Patient 1 (48 years of age) was classified as having a good response to treatment. The patient was referred from a gynecological ward of Gniezno County Hospital (Gniezo, Poland) in October 2007 with a suspected neoplastic process that extended from the ovary, for treatment at the. Surgical Gynecology Clinic of the Gynecological and Obstetrics Clinical Hospital (Poznan, Poland). On admission, vaginal and transabdominal ultrasounds were performed, which showed conglomerate tumors occupying the pelvis. This ovarian tumor had the following dimensions, 7×8 and 6×5.9 cm infiltrated the large intestine (descending colon and anus) and bladder. The level of the marker cancer antigen (CA) 125 was 207 IU/ml in the blood (normal reference values are \<35 IU ml). Subsequent to preparation, partial excision of the pelvic tumor, with reconstruction of the walls of the bladder and anastomosis of the proximal descending colon and the rectum was performed. Unfortunately, due to infiltration of the tumor into the left iliac vessels, the whole tumor was not removed Subsequent to a period of recuperation in November 2007, treatment was commenced with first-line chemotherapy, consisting of paclitaxel and cisplatin (intravenous infusion of paclitaxel 175 mg/m^2^ and 75 mg/m^2^ cisplatin per cycle lasting 3 h with 3 weeks break between chemotherapy cycles) which lasted continuously until February 2008. At the start of this stage of treatment, a lesion in the vicinity of the left iliac vessels were visible on transvaginal ultrasound, 1.0×0.7 cm in size, while the CA125 level was 50 IU/ml in the blood. Subsequent to a cycle of paclitaxel and cisplatin chemotherapy (intravenous infusion of paclitaxel 175 mg/m^2^ and 75 mg/m^2^ cisplatin per cycle lasting 3 h with 3 weeks break between chemotherapy cycles.), this lesion was invisible and the CA125 level was 13 IU/ml in the blood. At a follow-up in late April 2008, ultrasound examinations found recurrence in the vicinity of the left iliac vessels, with a dimension of 4×4×5 cm and the patient was admitted to the oncology clinic of the Gynecology and Obstetrics Gynecological Clinical Hospital (Poznan, Poland). It was decided to perform surgery to remove the lesion. Considering the high infiltration of the left iliac vessels and subsequent to consultation with a vascular surgeon, the lesion was not entirely removed, leaving a fragment of a tumor measuring \~0.5×0.5 cm around the left common iliac artery. The next stage of treatment was second-line chemotherapy consisting of cyclophosphamide and cisplatin (intravenous infusion of cyclophosphamide 750 mg/m^2^ and 75 mg/m^2^ cisplatin per cycle lasting 3 h with 3 weeks break between chemotherapy cycles, which started at the end of May 2008. However, subsequent to 2 cycles of chemotherapy, the patient had a strong anaphylactic reaction to the chemotherapy, which resulted in a change to topotecan (to 1.5 mg/m^2^ for 5 days every 3 weeks). The level of CA125 (7 IU/ml) in the blood had decreased to 3 IU/ml at the end of therapy, the baseline was following completion of the topotecan treatment. Chemotherapy was completed in late October/November 2008, with the ultrasound also revealing no pelvic lesions; it was decided to continue treatment on an outpatient basis, with one follow-up every 3 weeks. During a follow-up in late December 2008, a recurrence 7×5×5 cm in size was observed around the left iliac vessels. In addition, the patient experienced deterioration in general condition, including a lack of appetite, weakness and weight loss (12 kg within 7 weeks). At the request of the patient, further treatment was not commenced, and it was decided in consultation with the patient for palliative care to be administered at their place of residence. The patient succumbed in mid-January 2009. At the request of the family, no autopsy was performed.

#### Case 2

Patient 2 (50 years of age) was classified as having a good response to treatment. The patient presented to the gynecological clinic of the local hospital in Kościan (Kościan County Hospital) in February 2009 subsequent to the accidental detection of a polycystic solid tumor in the pelvic cavity, posterior to the uterus, during abdominal ultrasound. The patient was urgently admitted to the Surgical Gynecology Clinic of the Gynecological and Obstetrics Clinical Hospital in March 2009 and a transvaginal ultrasonography revealed a tumor 9×5×5 cm in size that was in contact with the ascending colon and bladder. The patient reported a history of partial hysterectomy in July 2007. The CA125 level in the blood was 175 IU/ml. Subsequent to preparation, surgery was performed to remove the lesions originating from the right ovary, with the macroscopically unchanged left ovary. Following a period of recovery, first-line chemotherapy consisting of paclitaxel and carboplatin (6 cycles intravenous infusion of paclitaxel, 175 mg/m^2^ lasting 3 h, followed by 400 mg/m^2^ carboplatin per cycle, with 3 weeks between cycles.) was commenced in mid-April 2009. Throughout the administration of chemotherapy, there were no lesions in the pelvic cavity and the level of the marker CA125 in the blood dropped between 40 IU/ml at the start of chemotherapy and 13 IU/ml at its completion. In the period between September 2009 and February 2013, the patient was admitted to the Surgical Gynecology Clinic of the Gynecological and Obstetrics Clinical Hospital. In March 2013 during a routine follow-up, a pelvic lesion 7×10×5 cm in size was identified in the right ovary. The patient was admitted to the clinic in order to perform surgery to remove the lesion. The CA125 level was 51 IU/ml. Underwent radical changes and the removal of deciding to start at the beginning of March 2013 chemotherapy (3 cycles of intravenous infusion of paclitaxel 175 mg/m^2^ and carboplatin 400 mg/m^2^ per cycle lasting 3 h with 3 weeks break between chemotherapy cycles). During the third course of chemotherapy, the patient developed an adverse reaction to carboplatin (palmar-plantar erythrodysesthesia) that resulted in carboplatin being replaced by cisplatin (3 cycles of intravenous infusion of 75 mg/m^2^ cisplatin per cycle; 3 weeks break between chemotherapy cycles). Chemotherapy was completed in August 2014, and the patient was referred for follow-up. The last follow-up took place in October 2014. No lesions were detected in the pelvic cavity and the level of CA125 in the blood was 10 IU/ml. The patient succumbed to cardiogenic shock in mid-December 2014. At the request of the family, no autopsy was performed.

#### Case 3

Patient 3 (49 years of age) was classified as being unresponsive to treatment. In October 2009, the patient was admitted to the Department of Gynecology, Konin district hospital (Konin, Poland) due to a pelvic tumor. On admission to the Surgical Gynecology Clinic of the Gynecological and Obstetrics Clinical Hospital, transvaginal ultrasonography revealed a solid lesion with multiple compartments that filled the entire pelvis, with smaller dimensions totaling 12×10×17 cm. The tumor infiltrated the bladder and bowel. There was no point in time at which the point where the cancer lesion came from could be reached. The level of CA125 in the blood was 156 IU/ml. Subsequent to preparation, non-radical resection of the tumor was performed, including the uterus and ovaries, a fragment of the wall of the bladder and a section of the descending colon. Among the surgically reconstructed section, colon end-to-side colon anastomosis was performed. However, a small residual section infiltrating the jejunum was left. Following a period of recuperation in mid-November 2009, first-line chemotherapy consisting of paclitaxel and carboplatin (6 cycles of intravenous infusion of paclitaxel 175 mg/m^2^ and 400 mg/m^2^ carboplatin per cycle lasting 3 h with 3 weeks break between chemotherapy cycles) was commenced. During the examination prior to the first treatment cycle, lesions were detected in the pelvis and the blood CA125 level was 21 IU/ml. Following 3 cycles of chemotherapy, pelvic free fluid appeared, and the amount of fluid increased in the following cycle. Prior to the last cycle of (February 2010) chemotherapy, a lesion that involved the bladder wall, 2×2×3 cm in size, was observed during the ultrasound. Due to the poor condition and increasing shortness of breath of the patient, the peritoneal cavity was punctured, and over 3 days, 5 l of fluid were removed. Subsequent to another week of hospitalization and further deterioration in the general condition of the patient, further treatment was not administered at the patient\'s request, and the patient was discharged. Palliative care was administered between discharge (beginning of April 2010) and early June 2010, when the patient succumbed to ovarian cancer.

#### Case 4

Patient 4 (49 years of age) was classified as being unresponsive to treatment. In November 2010, the patient was referred to Surgical Gynecology Clinic of the Gynecological and Obstetrics Clinical Hospital by a physician, due to the detection of bilateral ovarian tumors by screening ultrasound. On admission, transvaginal ultrasound was performed, and a solid tumor with central vascularization, measuring 2×1×2 cm, was identified in the left ovary, and a multi-element solid tumor located centrally with peripheral vasculature, measuring 4×3×5 cm, was identified in the right ovary. The level of CA125 in the blood was 410 IU/ml. A radical hysterectomy with removal of the two ovaries, tumors and lymph nodes was performed. Following a period of recovery, first-line chemotherapy consisting of carboplatin and paclitaxel (6 cycles of intravenous infusion of paclitaxel 175 mg/m^2^ and 400 mg/m^2^ carboplatin per cycle lasting 3 h with 3 weeks break between chemotherapy cycles) was commenced in mid-December 2010. At the starting of chemotherapy, the CA125 level in the blood was 47 IU/ml, and subsequent to the completion of chemotherapy, it was 46 IU/ml. In May 2011, subsequent to finishing the whole course of treatment, the patient was referred to the Surgical Gynecology Clinic of the Gynecological and Obstetrics Clinical Hospital for follow-up. In June 2011, ultrasound examinations observed a lesion 2×2×0.5 cm in size, which gradually widened (between December 2010 and May 2011) to 7×10×6 cm in size. There was also an increase in the level of CA125 in the blood to 211 IU/ml in February 2013. The patient did not agree to the proposed hospitalizations and surgical procedures. In February 2013, a painful lump 2×2 cm in size was observed in the postoperative scar. Subsequent to obtaining consent from the patient to perform the surgery, a localized lesion in the vagina was removed. In addition, a partly invasive bladder recurrence was removed by local resection of the bladder wall, and a tumor located in the subcutaneous tissue, which was identified as metastasis, was also removed. Following a period of recuperation, second-line chemotherapy consisting of paclitaxel and carboplatin (6 cycles of intravenous infusion of paclitaxel 175 mg/m^2^ and 400 mg/m^2^ carboplatin per cycle lasting 3 h with 3 weeks break between chemotherapy cycles) was commenced in April 2013. Prior to the fourth cycle of chemotherapy, transvaginal ultrasound was performed, and identified a localized bladder lesion 2×1×1 cm in size, which, despite treatment, gradually increased in size over 3 cycles (13 weeks). Subsequent to completion of chemotherapy treatment for the localized lesion (4×4×3 cm above the vagina) and the level of CA125 in the blood increased from the initial 13 IU/ml to 97 IU/ml subsequent to treatment. In April 2014, the patient refused to consent to the subsequent chemotherapy and self-discharged. In December 2014, the patient was presented again to the Surgical Gynecology Clinic of the Gynecological and Obstetrics Clinical Hospital with weight loss and weakness and was immediately admitted for treatment. Subsequent to improvement of blood morphology, renal function and the general condition of the patient, the proposed chemotherapy regimen Caelyx (doxorubicin) (6 cycles of 50 mg/m^2^ doxorubicin per cycle, with 3 weeks between chemotherapy cycles) was administered. In total, six cycles of chemotherapy were administered, which did not stop the growth of the localized lesions in the pelvic cavity. At the end of administrations, the dimensions were 7×5×5 cm and CA125 from level had increased from the original 136 IU/ml to 192 IU/ml. In May 2015, chemotherapy was again attempted, with the fourth-line chemotherapy consisting of paclitaxel and carboplatin (6 cycles of intravenous infusion of paclitaxel 175 mg/m^2^ and 400 mg/m^2^ carboplatin per cycle lasting 3 h with 3 weeks break between chemotherapy cycles), which was stopped after 3 courses due to the absence of treatment effects, and the request of the patient to be discharged and discontinue treatment. During the last follow-up, the lesion was 10×9×8 cm in size and the blood CA125 level was 625 IU/ml. The patient succumbed to ovarian cancer in late November 2015.

#### Genetic examination

The proceeding of a genetic examination was performed as previously described ([@b14-ol-0-0-6590]). Four formalin-fixed paraffin-embedded (FFPE) ovarian carcinoma tissue samples were obtained from the Cancer Pathology Department at Poznan University of Medical Sciences. The FFPE blocks were no older than 5 years.

In order to obtain a high content of cancer cells for DNA extraction, 5--10 sections (5-µm thick) were cut from each paraffin block, and a set of slides was prepared. One slide per patient was then stained routinely with hematoxylin and eosin to identify regions containing a high concentration of cancer cells. Based on this estimation, regions of interest were dissected from the unstained slides. The dissected cells were then put into a 1.5 Eppendorf tube and DNA was extracted using QIAamp DNA FFPE Tissue kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer\'s protocol. Following the extraction, DNA was inspected using NanoDrop spectrophotometer (NanoDrop; Thermo Fisher Scientific, Inc.) and the Qubit 2.0, Quant-iT™ PicoGreen^®^ dsDNA Assay kit (Thermo Fisher Scientific, Inc.). A final concentration of 12 ng/µl DNA in Tris-EDTA buffer (10 mM Tris-HCl, 0.1 mM disodium EDTA, pH 8) was than utilized for the OncoScan^®^ assay (Affymetrix, Inc., Santa Clara, CA, USA). In total, 80 ng of DNA (in 6.6 µl) from each sample were processed. The advantage of the OncoScan assay is possibility of simultaneous identification of copy number alterations, loss of heterozygosity (LOH) and somatic mutations (SMs) in a single experiment. This is possibly due to the use of molecular inversion probe (MIP) technology, and capturing \>220,000 small nucleotide polymorphism (SNP) genotypes focused on \~900 cancer locations, distributed across the genome. Another advantage is the ability to identify selected 'hotspot' somatic mutations in nine genes that particularly contribute to the development of various cancers \[tumor protein p53, B-Raf proto-oncogene, serine/threonine kinase, KRAS proto-oncogene, GTPase, epidermal growth factor receptor, isocitrate dehydrogenase 1, isocitrate dehydrogenase 2, phosphatase and tensin homolog, phosphoinositide-3-kinase catalytic subunit α (PIK3CA) and NRAS proto-oncogene, GTPase\]. The experimental procedure includes several steps. Probes were added to the sample DNA, and allowed to anneal at 58°C overnight (16--18 h) subsequent to an initial denaturation (95°C for 5 min). Samples was then split into two separate reactions, and proceeded as follows: dATP (A) and dTTP (T) (A/T) were added to one reaction, and dGTP (G) and dCTP (C) (G/C) were added to the second in order to conduct gap fill.

Unincorporated and non-circularized MIPs, as well as the remains of the genomic template, were removed by treatment with exonucleases (Affymetrix, Inc.). The circular MIPs that were gap-filled by the A/T or G/C nucleotides were cleaved using the HaeIII enzyme, and their linear form was amplified by PCR. Subsequently, the 120-bp PCR product was cut and the smaller (44-bp) fragment containing the specific SNP genotype was subjected for hybridization onto array. Prior to this, samples were mixed with hybridization buffer and injected into the cartridges for 16--18 h at 49°C and 0.013 × g. Following hybridization, cartridges were removed from the oven, and stained using the GeneChip^®^ Fluidics Station 450 (Affymetrix, Inc.), according to the manufacturer\'s protocol. Subsequent to staining and washing, arrays were scanned in GeneChip Scanner 3000 7G (Affymetrix, Inc.) and the fluorescence of clusters was measured in order to generate a DAT file. Cluster intensities values were automatically calculated using built-in algorithm from DAT files by the Affymetrix GeneChip Command Console software, version 4.0 (Affymetrix, Inc.), and a CEL file was created.

#### Genomic data analysis

CEL files were processed using OncoScan Console software, version 1.1.034 (Affymetrix, Inc.), to recalculate probe intensities into genomic landscape (OSCHP file) as well as a set of QC metrics (MAPD SNPQC and waviness). For each sample, a profile of copy number alterations was created, expressed by numerical values. The LOH profile was created for all samples, assuming a high confidence interval of ≥3 Mbp (ChAS option). The TuScan algorithm was also used for calculation of ploidy (i.e. 0, 66 or 100%). Somatic mutations were evaluated and viewed in the ChAS browser (Affymetrix, Inc.). The reliability of calls for SMs depends on the SNPQC parameter, and therefore it was necessary to obtain ndSNPQC ≥26 ('in-bounds') for all tested samples. The OncoScan assays are able to detect mutations by relying on the signal intensity of designed clusters, which is translated into the mutation score. This algorithm recognizes three basic thresholds for calls, termed 'Undetected' for an absence of SMs, and 'Lower confidence' or 'High confidence' for detected changes. In the present study, the default mutation score thresholds supplied in the software were used.

Results
=======

### Genomic studies

Genomic screening using Affymetrix OncoScan arrays resulted in the identification of large genomic rearrangements across all of the cancer tissues. In general, chromosome number changes were detected in all examined tissues. Ploidies were found in three out of four examined samples. Patients 1 and 2 showed incomplete tetraploidy, whereas patient 3 showed incomplete triploidy. Patient 4 showed diploidy, according to the TuScan algorithm, with hypoploidy of chromosomes 13 and 15. The detailed analysis of regions presenting LOH resulted in the detection of 152 LOH segments with a minimum 3 Mbp size ([Table I](#tI-ol-0-0-6590){ref-type="table"}). These findings are shown in [Fig. 1](#f1-ol-0-0-6590){ref-type="fig"}, and the location of each altered segment was depicted. Subsequently, unique overlapping regions in patients presenting sensitivity for treatment (patients 1 and 2) vs. patients showing resistance (patients 3 and 4) were assessed. For the first cohort, only 5 segments on chromosomes 4, 6, 8, 9 and 16 were identified ([Table II](#tII-ol-0-0-6590){ref-type="table"}; [Fig. 2](#f2-ol-0-0-6590){ref-type="fig"}). Within those regions, 10 cancer genes were identified using the COSMIC database. For the second cohort, 20 regions on chromosomes 3--5, 7--9, 10, 11, 14--16 and 19 were identified. Within the selected segments, 45 different cancer genes were found ([Table III](#tIII-ol-0-0-6590){ref-type="table"}; [Fig. 3](#f3-ol-0-0-6590){ref-type="fig"}). The identified LOH regions for all patients are presented in [Fig. 1](#f1-ol-0-0-6590){ref-type="fig"}.

The OncoScan arrays enabled the identification of \~100 common somatic mutations ([Table IV](#tIV-ol-0-0-6590){ref-type="table"}). In the present study, only one mutation was identified, in patient 4. The mutation affected the PIK3CA gene and lead to a glutamic acid-lysine substitution (p.E542K, c.1624G\>A; Cosmic ID, COSM760). Notably, the mutation was found in cancer tissue that was diploid and was showing only a hypoploidy of acrocentric chromosomes (chromosomes 13, 15, 18 and 22).

Discussion
==========

Ovarian cancer has the highest mortality rate among reproductive cancers and currently ranks as the fifth leading cause of cancer-associated mortalities among women. Despite the improvements achieved in ovarian cancer therapy over previous decades, the overall 5-year survival rate remains \<50% ([@b15-ol-0-0-6590]). Therefore, novel agents are necessary to improve the outcomes for ovarian cancer patients. In addition, it is important to understand and define the patients that are likely to be sensitive to treatment and have resistant disease. Ovarian cancer is a lethal gynecological disease that is characterized by peritoneal metastasis and increased resistance to conventional chemotherapies ([@b16-ol-0-0-6590]). This increased resistance and the ability of the cancer to spread is often attributed to the formation of multicellular aggregates or spheroids in the peritoneal cavity, which seed to abdominal surfaces and organs ([@b17-ol-0-0-6590]). Since the presence of metastatic implants is a predictor of poor survival, a better understanding of how spheroids form is critical to improving patient outcome, and may result in the identification of novel therapeutic targets ([@b16-ol-0-0-6590]). The most widely used tumor marker in ovarian cancer, often considered the 'gold standard', is CA125, which is elevated in 80% of epithelial ovarian cancers (EOCs) ([@b18-ol-0-0-6590]). CA125 is elevated in 50--60% of patients with stage I EOC and 75--90% of patients with advanced stage EOC ([@b19-ol-0-0-6590]). The sensitivity of CA125 to identify early stage disease is limited as a screening tool ([@b20-ol-0-0-6590]). Reliable clinical evidence demonstrates that human epididymis protein (HE4), used alone or in combination with CA125, substantially improves the accuracy of screening and/or disease monitoring ([@b21-ol-0-0-6590]). HE4, found primarily in the epithelia of normal genital tissues is elevated in EOC ([@b22-ol-0-0-6590]). HE4 has greater specificity in the premenopausal age group than CA125, since it does not appear to be expressed at high levels in benign conditions ([@b23-ol-0-0-6590]--[@b25-ol-0-0-6590]). The strongest risk factor of developing ovarian cancer is a family history of breast and ovarian cancer. It is known that \~15% of ovarian cancer patients in the Polish population carry mutations in the BRCA1 and BRCA2 genes ([@b26-ol-0-0-6590]). A small number of cases are also associated with Lynch syndrome and mutations in hMLH1, hMSH2, hMSH6, PMS1 and PMS2 in mismatch repair genes ([@b27-ol-0-0-6590]). Chemotherapy resistance is a common problem faced by patients diagnosed with EOC ([@b28-ol-0-0-6590],[@b29-ol-0-0-6590]). Currently there are no specific or sensitive clinical biomarkers that may be implemented to identify chemotherapy resistance and provide insight into prognosis. Resistance of tumors to chemotherapeutic drugs remains a major clinical challenge for ovarian cancer treatment. The limitations of clinical chemotherapy have been ascribed primarily to mechanisms that mediate drug resistance at the cellular level ([@b30-ol-0-0-6590]). Previous studies suggest that tumor cells have the ability to regulate genes that help to export, decrease uptake, or increase the metabolism of chemotherapeutic drugs. Newer data also suggest that interactions between tumor cells and the surrounding microenvironment allow for increased resistance of tumor cells to chemotherapy ([@b31-ol-0-0-6590]). It has been observed that although 40--60% of patients achieve a complete clinical response to first-line chemotherapy treatment \~50% of these patients relapse within 5 years and only 10--15% of patients presenting with advanced stage disease achieve long-term remission ([@b32-ol-0-0-6590]). It is hypothesized that the high relapse rate is, at least in part, due to resistance to chemotherapy, which may be inherent or acquired by altered gene expression. The patient response to chemotherapy for ovarian cancer is extremely heterogeneous and there are currently no tools to aid the prediction of sensitivity or resistance to chemotherapy and allow treatment stratification ([@b8-ol-0-0-6590]). Such a tool may markedly improve patient survival by identifying the most appropriate treatment on a patient-specific basis. A clinically applicable gene signature capable of predicting patient response to chemotherapy has not yet been identified. Research into a predictive model, as opposed to a prognostic model, may be highly beneficial and aid the identification of the most suitable treatment for patients. Although it has not yet been accomplished, progress within the field suggests that the development of a predictive model is possible ([@b8-ol-0-0-6590]). There is considerable variability between the approaches and success of existing studies in the literature, and there have been high levels of variation in the explanatory genes identified ([@b13-ol-0-0-6590]). The present study hypothesizes that, if more attention is paid to selecting the patients included, to control for treatment history, these gene signatures may be simplified and models that are able to predict the response to treatment may be developed.

Targeting molecular signatures, as well as signal transduction pathways for tumor sensitivity and resistance is essential for treatment and improving overall survival in patients with ovarian cancer ([@b33-ol-0-0-6590]). At present, an efficient molecular diagnostics for patients has not been established. The major goal of the present study was to reveal molecular hallmarks associated with, or even responsible for, the response of a patient to standard treatment. This knowledge facilitates the design and implementation of new therapies based on the genetic defect type. The identification of molecular signatures associated with chemo-response is a recent area of investigation. In ovarian adenocarcinoma, the OncoScan microarray technology has been performed to find genetic markers and locations that would be relevant in the prediction of response to chemotherapy. The OncoScan assay is efficient for the analysis of FFPE samples ([@b14-ol-0-0-6590]).

For the purposes of the present study, patients were divided into two categories, according to responsiveness to chemotherapy. In microarray analysis, the distribution of specific genetic factors between patients was compared. Significant variances in the occurrence of rearrangements were detected for both amplifications (gains) and deletions (losses). Deletions were more frequent in patients showing chemoresistance (14 losses) than in patients presenting with chemosensitivity (1 loss). However, none of the deletions were present in both patients in the same group. This discrepancy between the two patients in each cohort shows a high genetic heterogeneity of tumors. Detailed mapping data also revealed information on the LOH. The LOH phenomenon is of particular importance since it enables the tracing of loss of the normal alleles of tumor suppressor genes, to determine the tumor phenotype. Therefore, locations presenting high frequency of LOH are attractive candidates for harboring tumor suppressor mutations. In the present study, similar amounts of LOH were present in the two cohorts. In addition, the majority of the samples showed LOH at several loci. Numerous loci with LOH were common between the two cohorts. However, certain LOH were typical for patients with resistance to chemotherapy or patients presenting with chemosensitivity. Regions of typical LOH for chemosensitivity were located on chromosomes 4 (p16.3, q11) and 6 (p25.3) in the present study, whereas LOH associated with loci 3p21.3, 3p26.3, 6q23.3 and 11q14.1 were found exclusively in the chemoresistant cases.

The assessment of LOH in EOC focused on the role of genes located on the short arm of chromosome 3 (3p) in the development of disease. Deletions in regions 3p21.3 and 3p26.3 are common for such cases ([@b34-ol-0-0-6590]).

LOH in 6q23.3 affects the genes MYB, TNFAIP3 and ECT2 L. Only TNFAIP3 has been implicated in the inhibition of programmed cell death is and suggested to be a tumor suppressor gene ([@b35-ol-0-0-6590]). At present, the function the remaining genes is not associated with the pathogenesis of ovarian cancer. Furthermore, Shridhar *et al* ([@b36-ol-0-0-6590]) reported that deletion of the 6q23.3 region, which commonly presents LOH in ovarian cancer.

Notably, the commonly mutated genes for EOC, namely: CDH1; PRKN; BRCA1/2; and AKT1 were not identified in the present study. However, in patient 4, who showed chemotherapy resistance, a somatic PIK3CA mutation was identified. Mutation in this gene has been previously associated with ovarian cancer ([@b37-ol-0-0-6590]). Certain studies have confirmed that the PIK3CA/Akt/mammalian target of rapamycin pathway is commonly dysregulated in ovarian cancers ([@b38-ol-0-0-6590],[@b39-ol-0-0-6590]).

Chemotherapy response in ovarian cancer is a complex and unpredictable process that determines the course of the disease. In the present study, genetic regions associated with ovarian cancer that may play an important role in the context of treatment response were identified. However, additional studies on a larger cohort of patients are required, in order to reveal crucial pathways and molecular determinants that directly influence the disease course and its aggressiveness.

This study was supported by the Polish Ministry of Science and Education (grant no. 789/FNiTP/162/2013).
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###### 

LOH regions identified in all examined patients.

  No.    Sample              Type   Chrom.   Cytoband   Genomic location start   Genomic location end   Size (Kbp)   Gene count
  ------ ------------------- ------ -------- ---------- ------------------------ ---------------------- ------------ ------------
    1    1_189975.OSCHP      LOH    1        p21.3      115837919                96311795               19526.124    161
    2    4_208156_15.OSCHP   LOH    1        p31.3      89473522                 68095206               21378.316    96
    3    3_8376_10.OSCHP     LOH    1        p36.23     33275981                 7892870                25383.111    392
    4    3_8376_10.OSCHP     LOH    1        p36.33     4738355                  754191                 3984.164     97
    5    1_189975.OSCHP      LOH    1        p36.33     33760197                 754191                 33006.006    524
    6    3_8376_10.OSCHP     LOH    1        q23.3      180377339                163377535              16999.804    144
    7    3_8376_10.OSCHP     LOH    1        q31.2      197574134                191510124              6064.01      24
    8    2_203344_15.OSCHP   LOH    1        q32.1      216605071                200649365              15955.706    180
    9    2_203344_15.OSCHP   LOH    1        q43        249212878                237257823              11955.055    102
    10   3_8376_10.OSCHP     LOH    2        p21        90245035                 42993165               47251.87     302
    11   3_8376_10.OSCHP     LOH    2        p25.3      39767074                 21493                  39745.581    250
    12   2_203344_15.OSCHP   LOH    2        q11.2      112928815                101831270              11097.545    79
    13   1_189975.OSCHP      LOH    2        q13        141463604                114138191              27325.413    127
    14   2_203344_15.OSCHP   LOH    2        q36.1      228157661                224463413              3694.248     18
    15   3_8376_10.OSCHP     LOH    2        q36.3      243052331                230641762              12410.569    154
    16   2_203344_15.OSCHP   LOH    2        q36.3      243052331                230903874              12148.457    152
    17   3_8376_10.OSCHP     LOH    3        p21.31     51927415                 46001062               5926.353     143
    18   4_208156_15.OSCHP   LOH    3        p21.31     53323914                 50248426               3075.488     82
    19   3_8376_10.OSCHP     LOH    3        p26.3      11539955                 63410                  11476.545    69
    20   4_208156_15.OSCHP   LOH    3        p26.3      49346130                 63410                  49282.72     368
    21   4_208156_15.OSCHP   LOH    3        q22.3      164972840                138296967              26675.873    147
    22   3_8376_10.OSCHP     LOH    3        q25.32     168219437                157426328              10793.109    39
    23   3_8376_10.OSCHP     LOH    3        q27.1      197852564                184416008              13436.556    129
    24   3_8376_10.OSCHP     LOH    4        p15.1      35668267                 29950964               5717.303     1
    25   2_203344_15.OSCHP   LOH    4        p16.3      8060637                  71565                  7989.072     107
    26   1_189975.OSCHP      LOH    4        p16.3      49092454                 71565                  49020.889    278
    27   1_189975.OSCHP      LOH    4        q11        190915650                52684890               138230.76    611
    28   2_203344_15.OSCHP   LOH    4        q11        190915650                52684890               138230.76    611
    29   3_8376_10.OSCHP     LOH    4        q22.3      114068306                97748435               16319.871    90
    30   4_208156_15.OSCHP   LOH    4        q24        190915650                103271887              87643.763    337
    31   3_8376_10.OSCHP     LOH    4        q26        177478156                119815943              57662.213    207
    32   4_208156_15.OSCHP   LOH    5        p14.1      33066481                 28142098               4924.383     12
    33   3_8376_10.OSCHP     LOH    5        q11.1      68828372                 49441965               19386.407    87
    34   4_208156_15.OSCHP   LOH    5        q11.2      68828372                 51164114               17664.258    83
    35   1_189975.OSCHP      LOH    5        q11.2      68828372                 52864364               15964.008    77
    36   2_203344_15.OSCHP   LOH    5        q11.2      68828372                 55081693               13746.679    56
    37   3_8376_10.OSCHP     LOH    5        q13.2      90049057                 70306677               19742.38     109
    38   2_203344_15.OSCHP   LOH    5        q13.2      119919958                70306677               49613.281    206
    39   1_189975.OSCHP      LOH    5        q13.2      180698312                70306677               110391.635   749
    40   4_208156_15.OSCHP   LOH    5        q13.2      180698312                70306677               110391.635   749
    41   3_8376_10.OSCHP     LOH    5        q21.1      106861975                101206368              5655.607     9
    42   3_8376_10.OSCHP     LOH    5        q21.3      114957561                107853410              7104.151     33
    43   3_8376_10.OSCHP     LOH    5        q22.3      121539398                115180415              6358.983     20
    44   2_203344_15.OSCHP   LOH    5        q23.2      124880865                121481182              3399.683     11
    45   3_8376_10.OSCHP     LOH    5        q23.3      132783187                129632862              3150.325     34
    46   2_203344_15.OSCHP   LOH    5        q31.1      136935228                133568504              3366.724     33
    47   3_8376_10.OSCHP     LOH    5        q31.2      142559092                138965375              3593.717     106
    48   2_203344_15.OSCHP   LOH    5        q32        150654481                147480079              3174.402     48
    49   2_203344_15.OSCHP   LOH    5        q33.1      154336832                150789050              3547.782     21
    50   3_8376_10.OSCHP     LOH    5        q33.1      176675423                151738611              24936.812    137
    51   2_203344_15.OSCHP   LOH    5        q33.2      180698312                155277214              25421.098    200
    52   2_203344_15.OSCHP   LOH    6        p25.3      21704602                 204908                 21499.694    116
    53   1_189975.OSCHP      LOH    6        p25.3      58770502                 204908                 58565.594    708
    54   3_8376_10.OSCHP     LOH    6        q11.1      69746054                 61886392               7859.662     8
    55   1_189975.OSCHP      LOH    6        q11.1      170913051                61886392               109026.659   512
    56   2_203344_15.OSCHP   LOH    6        q22.32     170913051                126471760              44441.291    261
    57   3_8376_10.OSCHP     LOH    6        q23.3      170913051                135739354              35173.697    205
    58   4_208156_15.OSCHP   LOH    6        q23.3      170913051                138266430              32646.621    189
    59   3_8376_10.OSCHP     LOH    7        p15.3      35873540                 21882560               13990.98     118
    60   4_208156_15.OSCHP   LOH    7        p22.3      50700153                 41420                  50658.733    348
    61   1_189975.OSCHP      LOH    8        p23.1      26419805                 8094762                18325.043    147
    62   4_208156_15.OSCHP   LOH    8        p23.1      27024823                 8094762                18930.061    148
    63   3_8376_10.OSCHP     LOH    8        p23.1      30191040                 8094762                22096.278    182
    64   1_189975.OSCHP      LOH    8        p23.3      7004147                  172416                 6831.731     36
    65   3_8376_10.OSCHP     LOH    8        p23.3      7004147                  172416                 6831.731     36
    66   4_208156_15.OSCHP   LOH    8        p23.3      7004147                  172416                 6831.731     36
    67   4_208156_15.OSCHP   LOH    8        q11.21     53114569                 49845207               3269.362     5
    68   4_208156_15.OSCHP   LOH    8        q12.1      117682009                59515755               58166.254    254
    69   2_203344_15.OSCHP   LOH    8        q12.3      66046002                 62996038               3049.964     12
    70   1_189975.OSCHP      LOH    8        q13.3      111154532                71428716               39725.816    192
    71   3_8376_10.OSCHP     LOH    8        q24.22     140789847                134986490              5803.357     10
    72   2_203344_15.OSCHP   LOH    9        p22.3      24559653                 14364589               10195.064    59
    73   1_189975.OSCHP      LOH    9        p24.3      33434153                 204737                 33229.416    138
    74   4_208156_15.OSCHP   LOH    9        q21.11     78561334                 70984371               7576.963     37
    75   1_189975.OSCHP      LOH    9        q21.12     141054761                73134143               67920.618    659
    76   3_8376_10.OSCHP     LOH    9        q21.13     99234997                 74937502               24297.495    145
    77   2_203344_15.OSCHP   LOH    9        q21.13     93599890                 79064623               14535.267    67
    78   3_8376_10.OSCHP     LOH    9        q31.1      136241639                107839840              28401.799    301
    79   4_208156_15.OSCHP   LOH    9        q33.2      141054761                125422864              15631.897    316
    80   1_189975.OSCHP      LOH    10       p15.3      32764613                 126069                 32638.544    188
    81   1_189975.OSCHP      LOH    10       q23.1      135434303                82575777               52858.526    437
    82   4_208156_15.OSCHP   LOH    10       q23.1      135434303                82843903               52590.4      437
    83   3_8376_10.OSCHP     LOH    10       q23.1      114381720                87268004               27113.716    267
    84   3_8376_10.OSCHP     LOH    11       p11.2      51575951                 46089775               5486.176     59
    85   1_189975.OSCHP      LOH    11       p11.2      51575951                 48040260               3535.691     18
    86   1_189975.OSCHP      LOH    11       p15.5      3789206                  192763                 3596.443     112
    87   4_208156_15.OSCHP   LOH    11       p15.5      27025877                 192763                 26833.114    361
    88   3_8376_10.OSCHP     LOH    11       p15.5      38786252                 192763                 38593.489    422
    89   4_208156_15.OSCHP   LOH    11       q12.2      63386750                 60212296               3174.454     108
    90   1_189975.OSCHP      LOH    11       q13.4      80566396                 70719896               9846.5       108
    91   4_208156_15.OSCHP   LOH    11       q14.1      134938847                82560444               52378.403    405
    92   3_8376_10.OSCHP     LOH    11       q14.1      93535839                 84664703               8871.136     56
    93   3_8376_10.OSCHP     LOH    11       q22.1      118473385                99519603               18953.782    155
    94   1_189975.OSCHP      LOH    11       q22.3      116216759                108306235              7910.524     62
    95   1_189975.OSCHP      LOH    12       p13.33     12919325                 189399                 12729.926    215
    96   3_8376_10.OSCHP     LOH    12       q13.13     133818115                52051129               81766.986    724
    97   2_203344_15.OSCHP   LOH    12       q14.1      62234495                 59059674               3174.821     3
    98   2_203344_15.OSCHP   LOH    12       q21.33     133818115                89779996               44038.119    388
    99   4_208156_15.OSCHP   LOH    12       q23.1      133818115                96564524               37253.591    340
  100    3_8376_10.OSCHP     LOH    13       q11        111956103                19084822               92871.281    429
  101    2_203344_15.OSCHP   LOH    13       q11        115103150                19084822               96018.328    460
  102    4_208156_15.OSCHP   LOH    13       q11        115103150                19084822               96018.328    460
  103    3_8376_10.OSCHP     LOH    14       q11.2      35930195                 23299134               12631.061    116
  104    4_208156_15.OSCHP   LOH    14       q23.1      107282024                60071277               47210.747    465
  105    1_189975.OSCHP      LOH    14       q23.1      99873891                 60436201               39437.69     283
  106    3_8376_10.OSCHP     LOH    14       q32.2      107282024                100785616              6496.408     170
  107    1_189975.OSCHP      LOH    15       q11.2      78938567                 22752398               56186.169    617
  108    3_8376_10.OSCHP     LOH    15       q11.2      79548077                 22752398               56795.679    624
  109    4_208156_15.OSCHP   LOH    15       q11.2      102397317                22752398               79644.919    807
  110    2_203344_15.OSCHP   LOH    15       q24.2      79167603                 75948670               3218.933     42
  111    2_203344_15.OSCHP   LOH    16       p11.2      35271725                 31842847               3428.878     16
  112    3_8376_10.OSCHP     LOH    16       p13.3      23792157                 83886                  23708.271    366
  113    1_189975.OSCHP      LOH    16       p13.3      35271725                 83886                  35187.839    535
  114    1_189975.OSCHP      LOH    16       q11.2      90158005                 46461308               43696.697    420
  115    3_8376_10.OSCHP     LOH    16       q11.2      90158005                 46461308               43696.697    420
  116    1_189975.OSCHP      LOH    17       p13.3      22217883                 400958                 21816.925    399
  117    2_203344_15.OSCHP   LOH    17       p13.3      22217883                 400958                 21816.925    399
  118    3_8376_10.OSCHP     LOH    17       p13.3      22217883                 400958                 21816.925    399
  119    4_208156_15.OSCHP   LOH    17       p13.3      22217883                 400958                 21816.925    399
  120    1_189975.OSCHP      LOH    17       q11.1      45863219                 25326940               20536.279    472
  121    2_203344_15.OSCHP   LOH    17       q11.1      80263427                 25326940               54936.487    952
  122    3_8376_10.OSCHP     LOH    17       q11.1      80263427                 25326940               54936.487    952
  123    4_208156_15.OSCHP   LOH    17       q11.1      80263427                 25326940               54936.487    952
  124    1_189975.OSCHP      LOH    17       q23.2      80263427                 58390959               21872.468    320
  125    2_203344_15.OSCHP   LOH    18       p11.32     10493077                 2063183                8429.894     44
  126    4_208156_15.OSCHP   LOH    18       q12.1      78007784                 26057436               51950.348    215
  127    2_203344_15.OSCHP   LOH    18       q12.2      78007784                 36335674               41672.11     172
  128    3_8376_10.OSCHP     LOH    18       q12.3      78007784                 38349307               39658.477    169
  129    1_189975.OSCHP      LOH    18       q12.3      78007784                 42908725               35099.059    162
  130    1_189975.OSCHP      LOH    19       p13.3      4448843                  247231                 4201.612     154
  131    4_208156_15.OSCHP   LOH    19       p13.3      6222353                  247231                 5975.122     196
  132    3_8376_10.OSCHP     LOH    19       p13.3      9033548                  247231                 8786.317     277
  133    2_203344_15.OSCHP   LOH    19       q13.11     59093239                 35366074               23727.165    924
  134    4_208156_15.OSCHP   LOH    19       q13.2      56731955                 42241444               14490.511    616
  135    1_189975.OSCHP      LOH    19       q13.32     59093239                 46416646               12676.593    561
  136    4_208156_15.OSCHP   LOH    20       p13        16811434                 69093                  16742.341    139
  137    1_189975.OSCHP      LOH    20       q11.22     60126157                 34313296               25812.861    250
  138    2_203344_15.OSCHP   LOH    20       q13.2      58259236                 52721955               5537.281     49
  139    3_8376_10.OSCHP     LOH    20       q13.2      60139227                 52771260               7367.967     57
  140    1_189975.OSCHP      LOH    21       q11.2      48097610                 14344536               33753.074    295
  141    1_189975.OSCHP      LOH    22       q11.1      51213826                 16054712               35159.114    549
  142    4_208156_15.OSCHP   LOH    22       q11.1      51213826                 16054712               35159.114    549
  143    3_8376_10.OSCHP     LOH    22       q11.21     51213826                 19939352               31274.474    492
  144    2_203344_15.OSCHP   LOH    22       q11.21     51213826                 21028945               30184.881    467
  145    1_189975.OSCHP      LOH    X        p22.33     58412929                 177941                 58234.988    396
  146    3_8376_10.OSCHP     LOH    X        p22.33     58412929                 177941                 58234.988    396
  147    2_203344_15.OSCHP   LOH    X        q11.1      65127774                 61732393               3395.381     12
  148    3_8376_10.OSCHP     LOH    X        q11.1      76001785                 61732393               14269.392    102
  149    1_189975.OSCHP      LOH    X        q11.1      155219364                61732393               93486.971    623
  150    4_208156_15.OSCHP   LOH    X        q11.2      67429457                 63554561               3874.896     12
  151    3_8376_10.OSCHP     LOH    X        q21.31     92806132                 88265772               4540.36      3
  152    3_8376_10.OSCHP     LOH    X        q25        129607422                125678360              3929.062     18

LOH, loss of heterozygosity; Chrom., chromosome

###### 

The chromosomal regions showing chromosomal alterations identified in patients 1--2 showing sensitiveness for chemotherapy.

  No.   Type   Segment               Chrom.   Genomic location start   Genomic location end   Size (Kbp)   Cancer genes
  ----- ------ --------------------- -------- ------------------------ ---------------------- ------------ ---------------------------------
  1     loh    LOH_2\_15.OSCHP         4      52684890                 97836479               45151.589    FIP1L1, CHIC2, PDGFRA, KIT, KDR
  2     loh    LOH_2\_15.OSCHP         6          204908               21704602               21499.694    IRF4, DEK,
  3     loh    LOH_2\_15.OSCHP         9      14364589                 24559653               10195.064    NFIB, MLLT3, CDKN2A
  4     loh    LOH_2\_15.OSCHP       16       31842847                 35271725               3428.878     --
  5     loss   Loss1.5_2\_15.OSCHP     8      89900441                 95759698               5859.257     --

LOH, loss of heterozygosity; Chrom., chromosome.

###### 

The chromosomal regions with alterations identified in patients 3 and 4, who showed chemoresistance.

  No.   Type   Segment                Chrom.   Genomic location start   Genomic location end   Size        Genes
  ----- ------ ---------------------- -------- ------------------------ ---------------------- ----------- --------------------------------------------------------------
    1   loh    LOH_3\_10.OSCHP        3        63410                    11539955               11476.545   SRGAP3, FANCD2, VHL
    2   loh    LOH_3\_10.OSCHP        3        46001062                 51927415               5926.353    SETD2
    3   loh    LOH_3\_10.OSCHP        3        157426328                168219437              10793.109   MLF1
    4   loss   Loss1.0_4\_15.OSCHP    4        104892789                126864721              21971.932   TET2, IL2
    5   loss   Loss1.0_4\_15.OSCHP    4        160026316                190915650              30889.334   
    6   loss   Loss1.0_4\_15.OSCHP    5        51505664                 113875957              62370.293   IL6ST, PIK3R1, APC
    7   loh    LOH_3\_10.OSCHP        7        21882560                 35873540               13990.98    HNRN, PA2B1, HOXA9, HOXA11, HOXA13, JAZF1
    8   loss   Loss1.3_3\_10.OSCHP    7        23008207                 27115718               4107.511    
    9   loss   Loss1.7_3\_10.OSCHP    7        27127230                 32219657               5092.427    
  10    loss   Loss1.3_3\_10.OSCHP    7        32240424                 32817742               577.318     
  11    loss   Loss1.0_4\_15.OSCHP    8        172416                   26170975               25998.559   PCM1
  12    loss   Loss1.5_4\_15.OSCHP    9        126044009                136147702              10103.693   SET, FNBP1, ABL1, NUP214, TSC1, RALGDS
  13    loss   LOH_3\_8376_10.OSCHP   10       87268004                 114381720              27113.716   BMPR1A, PTEN, TLX1, NFKB2, SUFU, NT5C2, VTI1A, TCF7L2, FGFR2
  14    loh    LOH_4\_15.OSCHP        11       192763                   27025877               26833.114   HRAS, CARS, NUP98, LMO1, FANCF
  15    loh    LOH_3\_10.OSCHP        11       84664703                 93535839               8871.136    PICALM
  16    loss   LOH_3\_8376_10.OSCHP   14       100785616                107282024              6496.408    
  17    loss   Loss1.3_3\_10.OSCHP    15       71156952                 79214215               8057.263    PML
  18    loss   Loss1.5_4\_15.OSCHP    16       18069547                 19266457               1196.91     
  19    loss   Loss1.0_4\_15.OSCHP    19       247231                   5655792                5408.561    FSTL3, STK11, TCF3, GNA11, MAP2K2, SH3GL1, MLLT1
  20    loss   Loss1.7_3\_10.OSCHP    19       1550649                  8086055                6535.406    

LOH, loss of heterozygosity; Chrom., chromosome.

###### 

List of the drivers somatic mutations implemented into Affymetrix OncoScan Arrays.

  Mutation                                 Type                AA change                             CDS change                                              Cosmic ID
  ---------------------------------------- ------------------- ------------------------------------- ------------------------------------------------------- ------------------------
  NRAS:p.Q61R:c.182A\>G                    Missense            p.Q61R                                c.182A\>G                                               COSM584
  NRAS:p.Q61L:c.182A\>T                    Missense            p.Q61L                                c.182A\>T                                               COSM583
  NRAS:p.Q61K:c.181C\>A                    Missense            p.Q61K                                c.181C\>A                                               COSM580
  NRAS:p.G12V:c.35G\>T                     Missense            p.G12V                                c.35G\>T                                                COSM566
  NRAS:p.G12D:c.35G\>A                     Missense            p.G12D                                c.35G\>A                                                COSM564
  NRAS:p.G12S/C:c.34G\>A/T                 Missense            p.G12S\|\|p.G12C                      c.34G\>A\|\|c.34G\>T                                    COSM563\|\|COSM562
  IDH1:p.R132H:c.395G\>A                   Missense            p.R132H                               c.395G\>A                                               COSM28746
  PIK3CA:p.E542K:c.1624G\>A                Missense            p.E542K                               c.1624G\>A                                              COSM760
  PIK3CA:p.E545K:c.1633G\>A                Missense            p.E545K                               c.1633G\>A                                              COSM763
  PIK3CA:p.Q546K:c.1636C\>A                Missense            p.Q546K                               c.1636C\>A                                              COSM766
  PIK3CA:p.H1047R:c.3140A\>G               Missense            p.H1047R                              c.3140A\>G                                              COSM775
  PIK3CA:p.H1047L:c.3140A\>T               Missense            p.H1047L                              c.3140A\>T                                              COSM776
  EGFR:p.G719S:c.2155G\>A                  Missense            p.G719S                               c.2155G\>A                                              COSM6252
  EGFR:p.G719C:c.2155G\>T                  Missense            p.G719C                               c.2155G\>T                                              COSM6253
  EGFR:p.G719A:c.2156G\>C                  Missense            p.G719A                               c.2156G\>C                                              COSM6239
  EGFR:p.E746_A750del:c.2235_2249del15     In-frame            p.E746_A750delELREA                   c.2235_2249del15                                        COSM6223
  EGFR:p.E746_A750del:c.2236_2250del15     In-frame            p.E746_A750delELREA                   c.2236_2250del15                                        COSM6225
  EGFR:p.E746_T751\>A:c.2237_2251del15     Deletion In-frame   p.E746_T751\>A                        c.2237_2251del15                                        COSM12678
  EGFR:p.L747_E749P/del:c.2239_2248\>C/G   Various             p.L747_A750\>P\|\|p.L747_E749delLRE   c.2239_2248TTAAGAGAAG \>C\|\|c.2239_2247 delTTAAGAGAA   COSM12 382\|\|COSM6218
  EGFR:p.L747_T751del:c.2240_2254del15     In-Frame            p.L747_T751delLREAT                   c.2240_2254del15                                        COSM12369
  EGFR:p.L747_P753\>S:c.2240_2257del18     Deletion In-frame   p.L747_P753\>S                        c.2240_2257del18                                        COSM12370
  EGFR:p.V769_D770insASV:c.2307_2308ins9   In-frame            p.V769_D770insASV                     c.2307_2308ins GCCAGCGTG                                COSM12376
  EGFR:p.D770_N771insSVD:c.2311_2312ins9   In-frame            p.D770_N771insSVD                     c.2311_2312ins GCGTGGACA                                COSM13428
  EGFR:p.H773_V774insNPH:c.2319_2320ins9   In-frame            p.H773_V774insNPH                     c.2319_2320ins AACCCCCAC                                COSM12381
  EGFR:p.T790M:c.2369C\>T                  Missense            p.T790M                               c.2369C\>T                                              COSM6240
  EGFR:p.L858R:c.2573T\>G                  Missense            p.L858R                               c.2573T\>G                                              COSM6224
  EGFR:p.L861Q:c.2582T\>A                  Missense            p.L861Q                               c.2582T\>A                                              COSM6213
  BRAF:p.V600K:c.1798_1799GT\>AA           Missense            p.V600K                               c.1798_1799GT\>AA                                       COSM473
  BRAF:p.V600E:c.1799T\>A                  Missense            p.V600E                               c.1799T\>A                                              COSM476
  BRAF:p.G469E:c.1406G\>A                  Missense            p.G469E                               c.1406G\>A                                              COSM461
  BRAF:p.G469A:c.1406G\>C                  Missense            p.G469A                               c.1406G\>C                                              COSM460
  PTEN:p.R130G:c.388C\>G                   Missense            p.R130G                               c.388C\>G                                               COSM5219
  PTEN:p.R130\*:c.388C\>T                  Nonsense            p.R130\*                              c.388C\>T                                               COSM5152
  PTEN:p.R130Q/fs\*4:c.389G\>A/delG        Various             p.R130Q\|\|p.R130fs\*4                c.389G\>A\|\|c.389delG                                  COSM5033\|\|COSM5817
  PTEN:p.R159S:c.477G\>T                   Missense            p.R159S                               c.477G\>T                                               COSM5287
  PTEN:p.R233\*:c.697C\>T                  Nonsense            p.R233\*                              c.697C\>T                                               COSM5154
  PTEN:p.P248fs\*5:c.741_742insA           Frame-Shift         p.P248fs\*5                           c.741_742insA                                           COSM4986
  PTEN:p.K267fs\*9:c.800delA               Frame-Shift         p.K267fs\*9                           c.800delA                                               COSM5809
  KRAS:p.A146P:c.436G\>C                   Missense            p.A146P                               c.436G\>C                                               COSM19905
  KRAS:p.Q61H:c.183A\>T                    Missense            p.Q61H                                c.183A\>T                                               COSM555
  KRAS:p.Q61H:c.183A\>C                    Missense            p.Q61H                                c.183A\>C                                               COSM554
  KRAS:p.Q61K/K:c.180_181TC\>TA/AA         Missense            p.Q61K                                c.181C\>A\|\|c. 180_181TC\>AA                           COSM549\|\|COSM87298
  KRAS:p.G13D:c.38G\>A                     Missense            p.G13D                                c.38G\>A                                                COSM532
  KRAS:p.G12D/V:c.35G\>A/T                 Missense            p.G12D\|\|p.G12V                      c.35G\>A\|\|c.35G\>T                                    COSM521\|\|COSM520
  KRAS:p.G12A:c.35G\>C                     Missense            p.G12A                                c.35G\>C                                                COSM522
  KRAS:p.G12C/S:c.34G\>T/A                 Missense            p.G12C\|\|p.G12S                      c.34G\>T\|\|c.34G\>A                                    COSM516\|\|COSM517
  IDH2:p.R172K:c.515G\>A                   Missense            p.R172K                               c.515G\>A                                               COSM33733
  IDH2:p.R140Q:c.419G\>A                   Missense            p.R140Q                               c.419G\>A                                               COSM41590
  TP53:p.R306\*:c.916C\>T                  Nonsense            p.R306\*                              c.916C\>T                                               COSM10663
  TP53:p.R282W:c.844C\>T                   Missense            p.R282W                               c.844C\>T                                               COSM10704
  TP53:p.R273H/L:c.818G\>A/T               Missense            p.R273H\|\|p.R273L                    c.818G\>A\|\|c.818G\>T                                  COSM10660\|\|COSM10779
  TP53:p.R273C/S:c.817C\>T/A               Missense            p.R273C\|\|p.R273S                    c.817C\>T\|\|c.817C\>A                                  COSM10659\|\|COSM43909
  TP53:p.R249S:c.747G\>T                   Missense            p.R249S                               c.747G\>T                                               COSM10817
  TP53:p.R248Q/L:c.743G\>A/T               Missense            p.R248Q\|\|p.R248L                    c.743G\>A\|\|c.743G\>T                                  COSM10662\|\|COSM6549
  TP53:p.R248W:c.742C\>T                   Missense            p.R248W                               c.742C\>T                                               COSM10656
  TP53:p.G245S/C:c.733G\>A/T               Missense            p.G245S\|\|p.G245C                    c.733G\>A\|\|c.733G\>T                                  COSM6932\|\|COSM11081
  TP53:p.Y220C:c.659A\>G                   Missense            p.Y220C                               c.659A\>G                                               COSM10758
  TP53:p.R213\*:c.637C\>T                  Nonsense            p.R213\*                              c.637C\>T                                               COSM10654
  TP53:p.R196\*:c.586C\>T                  Nonsense            p.R196\*                              c.586C\>T                                               COSM10705
  TP53:p.H179R:c.536A\>G                   Missense            p.H179R                               c.536A\>G                                               COSM10889
  TP53:p.C176F:c.527G\>T                   Missense            p.C176F                               c.527G\>T                                               COSM10645
  TP53:p.R175H:c.524G\>A                   Missense            p.R175H                               c.524G\>A                                               COSM10648
  TP53:p.Y163C:c.488A\>G                   Missense            p.Y163C                               c.488A\>G                                               COSM10808
  TP53:p.V157F:c.469G\>T                   Missense            p.V157F                               c.469G\>T                                               COSM10670

[^1]: Contributed equally
